Q1 2022 Results
Company overview
Financial performance
Financial review
2022 priorities
Appendix
Innovation: Pipeline overview
Innovation: Clinical trials
References
Abbreviations
Q1 2022 free cash flow decreased to USD 0.9bn mainly due to the
loss of the Roche dividend in the prior year quarter
Group free cash flow¹
USD bn, % USD
1.6
-42%
Key drivers vs. PY
-
-
0.9
+
Lower dividends from associated companies
(PY Roche cash inflow of USD 0.5bn)
Unfavorable working capital
Favorable hedging results
Q1 2021
Q1 2022
Excluding PY Roche annual dividend, free cash flow declined -14% (USD)
1. Free cash flow is a non-IFRS measure. An explanation of non-IFRS measures can be found on page 35 of the Condensed Interim Financial Report.
31 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation